Menu
Following a buy and build strategy, SynBiotic supports & consolidates the
strongest players in the cannabinoids industry under one roof
Synbiotic: A plattform for exponational growth
Wir unterstützen nicht nur mit Geld sondern mit strategischen Advice sowie Netzwerk und Erfahrung.
Our R&D portfolio will create new products, formulations and IP and conduct studies to:
We execute minority share investments in these companies, in order to get preferential access to the technology.
Our production & biotech companies convert the innovation generated by R&D into market-ready products.
We target >50% ownership of our companies.
With our medical and DTC portfolio we are acquiring and building profitable brands within our verticals to generate revenue.
We target >50% ownership of our companies.
A strong core team with best-in-class portfolio CEOs & advisors
Lars Müller
CEO
Serial entrepreneur with over 10 years experience in scaling profitable companies.
In-depth industry know-how from seed to shelf, genetics, extraction methods & analytics such as product development. He is active in the cannabinoid business since 2015
Sebastian Stietzel
Chairman of the
Supervisory-Board
As a serial entrepreneur his strength lies in strategy, ops and in coaching senior leadership, with particular expertise in post-merger-integration and capital market fitness. Sebastian has a master’s degree in business administration with a focus on IT supported marketing and human resources.
Dr. Marlon Braumann
Member of the
Supervisory-Board
Dr. Marlon Braumann is a Serial Entrepreneur and one of the founding partners of the European VC fund Elevat3 Capital – an investment fund mainly focused on biotech, medtech, and fintech investments. Apart from that, Mr. Braumann is the founder of the global wildlife trust AMES Foundation.
Thomas Hanke
Member of the
Supervisory-Board
Mr. Hanke has extensive transaction experience (private equity, venture capital, growth capital & PIPE transactions) and has, in addition to his work as an investor, also carried out various operational interim mandates within the scope of portfolio management.
Dr. Le Roy Dowey
CEO of Greenlight Pharmaceutical LTD
Following his post-doctoral research, Le Roy became Quality Assurance Officer for Ulster’s Biomedical Sciences Research Institute (BMSRI). Le Roy holds a BSc (Hons) in Biochemistry from Queen’s University, Belfast and a PhD in Nutritional Biochemistry at Ulster University (2002). Le Roy joined the GreenLight Team in June 2018 and is now CEO.
As a scientist and a pharma expert, Dr. James Linden has built a world-class research network and the unique ability to aim R&D efforts at the most promising commercial opportunities. James holds a PhD in Biochemistry in the Department of Ophthalmology, Queens University Belfast.
Rainer Seiler
Co-Founder & Shareholder
Cannexo Pharma GmbH
Rainer Seiler has many years of leadership experience, including as Managing Director (Zur Rose Gruppe), as General Sales Manager (ratiopharm) and as Director Key Account Management within the pharmaceutical Industry (Rx, OTC, Gx), as well as with wholesalers and mail-order-pharmacy-companies.
and many more …
Lorem ipsum dolor sit ame consectetur adipiscing elit,
sed do eiusmod tempor incididunt ut labore.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Regulations, market, and customer readiness make CBD the most promising cannabinoid to start with, building a solid foundation for our platform
While the legalization of recreational THC is expected to come within the next years, we will start shifting our focus towards THC once the current regulatory framework has eased.
While the legalization of recreational THC is expected to come within the next years, we will start shifting our focus towards THC once the current regulatory framework has eased
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Making Cannabinoids accessible.